Ocular Therapeutix (NASDAQ: OCUL) reported Q2 EPS of ($0.26), $0.04 worse than the analyst estimate of ($0.22). Revenue for the quarter came in at $16.44 million versus the consensus estimate of $15.85 million.

For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.